Oh yeh, the patents..
From the google search: "Acute promyelocytic leukemia is invariably associated with gene fusions involving the retinoic acid receptor a (RARa) and one of five different partners, PML, PLZF, NPM, NuMA, and STAT5b. Patients with this disease respond to treatment with the RARa ligand, all trans retinoic acid (ATRA). Dominant negative mutants of RARa enhance mast cell development and reduce granulocyte and macrophage development in multipotential haematopoietic cell lines, and also block myeloid development in transduced murine bone marrow. Although targeted disruption of RARa in the mouse has little effect on haematopoiesis, in vitro studies revealed an increased proportion of morphologically immature granulocytes in RARa1/RAR? double mutants. In addition to this, in vitro studies suggest a role for the thyroid hormone receptor in erythropoiesis and for the PPAR? in monocyte/macrophage development. A role for the vitamin D receptor in myeloid differentiation is suggested by 1,25-dihydroxyvitamin D3-induced terminal differentiation and cell cycle arrest of a variety of leukaemic cell lines. Although little is known of the downstream genes regulated by NRs in haematopoiesis, evidence suggests that the cdk inhibitor p21 and the transcription factor C/EBPe may be targets of RARa in myelopoiesis."
How is the average investor to understand this? There's a lot of hub bub on Ihub but nothing in the scientific community.
News 
Market Data 
Discover 
